Keros Therapeutics Sees Unusually Large Options Volume (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS) saw some unusual options trading activity on Friday. Traders bought 4,215 put options on the stock. This is an increase of 287% compared to the typical daily volume of 1,090 put options.

Keros Therapeutics Stock Down 0.5 %

KROS opened at $12.18 on Friday. The company has a 50-day moving average price of $10.91 and a 200 day moving average price of $30.80. The company has a market cap of $494.05 million, a PE ratio of -2.34 and a beta of 1.39. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, sell-side analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MetLife Investment Management LLC increased its holdings in shares of Keros Therapeutics by 6.0% in the 4th quarter. MetLife Investment Management LLC now owns 18,098 shares of the company’s stock valued at $286,000 after acquiring an additional 1,027 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after purchasing an additional 1,100 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after buying an additional 1,372 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Keros Therapeutics by 7.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company’s stock valued at $303,000 after buying an additional 1,386 shares in the last quarter. Finally, Virtus ETF Advisers LLC grew its position in shares of Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after buying an additional 1,998 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Truist Financial reduced their price objective on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Cantor Fitzgerald cut shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Finally, Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.